Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 13/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 10/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15011535 | 0.82 | CTSL (0.36) | SLC6A2TSHROPRM1OPRD1OPRK1 | |
| SCHEMBL625124 | 0.81 | ADRB2 (0.38) | SLC6A2SLC6A4SLC6A3ALDH1A1MAPT | |
| SCHEMBL2467274 | 0.80 | TRPA1 (0.35) | HPGDTSHROPRM1OPRD1OPRK1 | |
| SCHEMBL3362836 | 0.80 | TRPA1 (0.35) | HPGDTSHROPRM1OPRD1OPRK1 | |
| SCHEMBL625393 | 0.78 | SLC6A2 (0.43) | SLC6A2SLC6A4SLC6A3OPRM1OPRD1 | |
| SCHEMBL3360485 | 0.73 | TRPA1 (0.38) | ALDH1A1MAPTTSHRHSD17B10OPRM1 | |
| SCHEMBL2436694 | 0.73 | TRPA1 (0.38) | ALDH1A1MAPTTSHRHSD17B10OPRM1 | |
| SCHEMBL624400 | 0.72 | SLC6A2 (0.38) | SLC6A2SLC6A4ALDH1A1OPRM1OPRD1 | |
| SCHEMBL15011397 | 0.71 | CTSL (0.36) | ALDH1A1 | |
| SCHEMBL14991566 | 0.70 | GAA (0.41) | SLC6A2SLC6A4SLC6A3ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9156788-B2 | TRPV3 modulators | ABBVIE INC. (US) | 2015-10-13 | — | — | US | disclosed |
| EP-2603490-A1 | NOVEL TRPV3 MODULATORS | AbbVie Inc. (US) | 2013-06-19 | — | — | EP | disclosed |
| US-20130150409-A1 | NOVEL TRPV3 MODULATORS | ABBVIE INC. (US) | 2013-06-13 | — | — | US | disclosed |
| WO-2012019315-A1 | NOVEL TRPV3 MODULATORS | ABBOTT LABORATORIES (US) | 2012-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150409-A1 | NOVEL TRPV3 MODULATORS | TRPV3, TRPV4, TRPV5 | SLC6A2 1774/4885SLC6A4 511/4885SLC6A3 717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.